OTLC - Oncotelic Therapeutics Inc

From OTC Wiki
Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin) and VDA agents (Oxi4503/CA4P) against viral infections and various tumors including three rare pediatric tumors (DIPG, Melanoma, and AML). The program is being funded by our partner GMP through a JV that we are intend to take IPO. 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas).

OTC Market: OTCQB

Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin) and VDA agents (Oxi4503/CA4P) against viral infections and various tumors including three rare pediatric tumors (DIPG, Melanoma, and AML). The program is being funded by our partner GMP through a JV that we are intend to take IPO. 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas).

Jump to: Wiki | News | Links | FAQs | Opinions

Edit Wiki page
Become Wiki Editor
Learn to edit
OTLC Stock - Oncotelic Therapeutics Inc
OTLC Stock - Oncotelic Therapeutics Inc

About Oncotelic[edit]

Oncotelic Therapeutics, Inc (OTC:OTLC) is a pre-revenue stage pharmaceutical development company based in Agoura Hills, CA. The company is in the process of developing treatments for rare and orphan diseases and conditions. Currently, treatment development is in progress for COVID-19, Parkinson’s Disease, DIPG, and PDAC.[1]

Development Pipeline[edit]

ArtiVeda/ArtiShield[edit]

This treatment is derived from the plant Artemisia, which has shown to be effective at safely inhibiting the the COVID-19 virus from multiplying. Artemisinin derivatives are used to treat malaria. More Information.[2]

OT-101[edit]

OT-101 is a treatment for both adult and pediatric brain tumors. Oncotelic submitted a clinical study protocol to the United States Food and Drug Administration in November, 2022, for the initiation of “G101”, which is a Phase 1 Trial for OT-101. OT-101 is a treatment for patients with recurrent or relapsed DMG. DMG in children is a very aggressive brain tumor with an expected survival rate of less than one year following radiation therapy.[3]

CA4P[edit]

CA4P is a vascular disrupting agent proposed for use in combination with Ipilimumab to treat solid tumors, particularly adult and pediatric melanoma. In May, 2020, Oncotelic received Rare Pediatric Disease Designation for CA4P from the FDA.[2]

Oxi4503[edit]

Oxi4503 is a treatment forf liquid tumors, particularly those associated with childhood leukemia. The FDA has granted the company’s request to designate OXi4503 for treatment of myeloid leukemia.[2]

AL-101[edit]

AL-101 is a treatment for Parkinson Disease via intranasal delivery of Apomorphine.[2]

Management[edit]

Key leaders[4]

Vuong Trieu, PhD. – CEO and Chairman[edit]

Served as President and CEO of Abraxane  developer Igdrasol, Board Director of Cenomed, Director of Pharmacology, Pharmacokinetics, and Biology at Abraxis

Led development in albumin encapsulated therapeutics,  CNS drugs, and a platform for platform for small molecules, mirRNA, kinases.

A member of many professional organizations, including ENDO, ASCO and AACR

Amit Shah - CFO[edit]

Served as Chief Financial Officer at publicly traded biotechnology company Marina Biotech, Inc.; Vice President of Finance & Accounting and Acting CFO at Insightra Medical Inc.; VP Finance and Acting Chief Financial Officer at IgDraSol Inc.; Corporate Controller & Director of Finance at ISTA Pharmaceuticals; Controller at Spectrum Pharmaceuticals; Chief Financial Officer at management consulting firm Eagle Business Performance Services.

Anthony Maida, Ph.D., MA, MBA, BA, BA – Chief Clinical Officer[edit]

Current focus is on immunotherapy of cancers and infectious disease.  

Served as Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc. with responsibility for operations oversight; Vice President of Clinical Research and General Manager, Oncology at PharmaNet, Inc.; Chairman and Director of BioConsul Drug Development Corporation

Negotiated licensing agreements with top tier pharmaceutical firms including Astra Zeneca, Eli Lilly, RCT Corporation, Pfizer, MD Anderson, Novartis, Yale University, and Stanford University,

  1. Yahoo Finance. OTLC Stock Quote. Retrieved on 12/1/2022.
  2. 2.0 2.1 2.2 2.3 Oncotelic.com. Oncotelic Pipeline. Retrieved on 12/1/2022.
  3. OTC Markets. Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas. November 8, 2022.
  4. Oncotelic.com. About Us. Retrieved on 12/1/2022.


Create News


Wed, 13:03 January 25, 2023 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Wed, 13:01 November 30, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 14:01 November 21, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Wed, 13:01 November 16, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Tue, 12:34 November 8, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Wed, 12:56 September 28, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 13:01 August 22, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Wed, 11:02 May 25, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 15:15 May 23, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Wed, 12:01 May 18, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Wed, 11:02 May 4, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 11:01 April 18, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Thu, 14:01 April 7, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 11:02 April 4, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Oncotelic Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |







More News: Company News | OTC Markets

OTLC Stock

As of 1/6/2023 there were 390,827,577 shares of OTLC stock outstanding.

As of 12/30/2022 short interest was 33,039 shares, which represents 1 day to cover.

Symbol change from MATN to OTLC on 3/30/2021.

Edit Links page


Create FAQs page


No opinions so far.

Please login or register to post your opinion.